Equities research analysts expect that Scpharmaceuticals Inc (NASDAQ:SCPH) will report earnings per share of ($0.51) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Scpharmaceuticals’ earnings. The highest EPS estimate is ($0.50) and the lowest is ($0.51). The business is scheduled to report its next quarterly earnings report on Tuesday, June 19th.
According to Zacks, analysts expect that Scpharmaceuticals will report full year earnings of ($2.78) per share for the current year, with EPS estimates ranging from ($2.90) to ($2.66). For the next financial year, analysts forecast that the company will report earnings of ($2.34) per share, with EPS estimates ranging from ($2.36) to ($2.32). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings data on Tuesday, March 20th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.27).
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Monashee Investment Management LLC bought a new position in shares of Scpharmaceuticals during the fourth quarter worth approximately $230,000. Bank of New York Mellon Corp bought a new position in shares of Scpharmaceuticals during the fourth quarter worth approximately $414,000. Millennium Management LLC bought a new position in Scpharmaceuticals during the 4th quarter worth $462,000. Goldman Sachs Group Inc. bought a new position in Scpharmaceuticals during the 4th quarter worth $653,000. Finally, Bain Capital Public Equity Management LLC bought a new position in Scpharmaceuticals during the 4th quarter worth $1,291,000. Institutional investors own 44.22% of the company’s stock.
Shares of NASDAQ SCPH traded down $0.06 during trading hours on Friday, reaching $11.20. 1,758 shares of the stock were exchanged, compared to its average volume of 51,720. The firm has a market cap of $216.49 and a P/E ratio of -1.39. The company has a current ratio of 24.12, a quick ratio of 24.12 and a debt-to-equity ratio of 0.09. Scpharmaceuticals has a 52 week low of $10.72 and a 52 week high of $18.17.
TRADEMARK VIOLATION NOTICE: “-$0.51 EPS Expected for Scpharmaceuticals Inc (SCPH) This Quarter” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3335244/0-51-eps-expected-for-scpharmaceuticals-inc-scph-this-quarter.html.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix for the treatment of worsening or decompensated heart failure outside of the inpatient setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.